Reducing variability in gene expression: bottlenecks and solutions
Bio Pharma Dive
NOVEMBER 18, 2024
Explore solutions to reduce variability in gene expression during cell line development.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Bio Pharma Dive
NOVEMBER 18, 2024
Explore solutions to reduce variability in gene expression during cell line development.
Pharmaceutical Technology
NOVEMBER 28, 2022
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. This includes an upfront payment of $2m from AstraZeneca.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
MAY 6, 2021
Jude Children’s Research Hospital scientists have developed a highly efficient method to address a major challenge in biology–identifying the genetic ‘switches’ that regulate gene expression. Credit: St. Jude Children’s Research Hospital St.
BioSpace
OCTOBER 20, 2022
Kite Pharma entered into a global licensing deal with Refuge Biotechnologies to leverage the latter's propriety gene expression plaform and develop potential blood cancer therapies.
XTalks
AUGUST 5, 2020
Single cell RNA sequencing technology has been extensively applied to understand heterogeneity among tumor cells, within the tumor microenvironment and during cell development. Visium Spatial Gene Expression Solution. On Visium Gene Expression slides, there are areas called capture areas, which have a lawn of barcode on them.
Pharmaceutical Technology
JULY 29, 2022
Ultragenyx uses adeno-associated virus 8 (AAV8) gene therapy to induce stable OTC gene expression. This treatment activates the OTC gene so that ammonia can be removed from the blood. In CAMP4’s approach, regRNAs are drugged with antisense oligonucleotides to control the direction of gene expression.
Camargo
JULY 8, 2021
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The report is a useful read to keep current on a topic of interest at the FDA and in drug development as a whole.
Scienmag
SEPTEMBER 30, 2021
Rhizobium-legume symbioses lead to the development of new plant organs on the roots […]. Crop legumes are an integral part of sustainable agriculture, as several of these species represent an important protein source for both human and animal populations.
Scienmag
JULY 6, 2022
A University of Minnesota Twin Cities-led team has developed a new technique that allows scientists and engineers to, for the first time, visualize mRNA molecules in the brains of living mice.
Scienmag
FEBRUARY 18, 2021
Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development on February 18.
Scienmag
MAY 16, 2022
Just as it’s hard to understand a conversation without knowing its context, it can be difficult for biologists to grasp the significance of gene expression without knowing a cell’s environment.
Scienmag
DECEMBER 22, 2020
Blocking gene expression in mitochondria in mice stops cancer cells from growing Credit: Hauke S. Hillen A newly developed compound starves cancer cells by attacking their “power plants” – the so-called mitochondria. The new compound prevents the genetic information within mitochondria from being read.
BioSpace
JULY 11, 2022
Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.
Pharmaceutical Technology
JANUARY 24, 2023
The investigational adeno-associated virus (AAV) gene therapy candidate NGN-401 is claimed to be the first to deliver the full-length human MECP2 gene using the company’s Expression Attenuation via Construct Tuning (EXACT) gene regulation technology.
BioTech 365
DECEMBER 1, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Researchers identify key RNA “gatekeeper” in gene expression, pointing to possible new drug targets.An
Scienmag
DECEMBER 28, 2021
Philadelphia, December 28, 2021 – In the central nervous system, microglial cells play critical roles in development, aging, brain homeostasis, and pathology. Recent studies have shown variation in the gene-expression profile and phenotype of microglia across brain regions and between different age and disease states.
Scienmag
DECEMBER 10, 2020
Credit: Nucleic Acids Research Scientists at Tokyo Institute of Technology decipher how to quantitatively assess the effects of specific epigenetic changes on the rate of transcription by developing a mathematical model. For this, they successfully generated reconstituted chromatin bearing histone modifications in vitro.
Drug Discovery Today
APRIL 24, 2023
Hussman Institute for Human Genomics at the University of Miami Miller School of Medicine have found that variations in chromatin accessibility, and thus gene expression, may explain why people of European descent with APOE4 gene variants have a greater risk of developing Alzheimer’s disease than people of African descent with similar genetics.
Medical Xpress
FEBRUARY 15, 2023
Traffic noise may play an essential role in the development and deterioration of ischemic heart disease.
pharmaphorum
NOVEMBER 12, 2021
Researchers in the US have developed an artificial intelligence-based tool that is able to predict COVID-19 symptoms and suggest which FDA-approved drugs might be used to treat patients. It could also be made more powerful by incorporating personal genetic information and gene expression profiles in tissues such as the lungs, they suggest.
XTalks
FEBRUARY 21, 2025
Related: Obesity-Focused Metsera Launches IPO Amid Much Anticipation Aardvarks approach centers on developing novel, small-molecule drugs that harness the bodys natural hunger-regulating mechanisms. Alongside ARD-101, Aardvark is developing ARD-201, a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 inhibitor.
XTalks
MARCH 26, 2025
Here are five key examples of current research and innovation driving the field forward between 2024 and early 2025: Third-Generation Antiseizure Medications Show Promise Recent clinical data shared in Epilepsia spotlighted Xcopri (cenobamate), developed by SK Life Science.
Pharmaceutical Technology
AUGUST 11, 2022
There is a clear correlation between the INHBE gene and metabolic syndrome, particularly T2D and coronary heart disease, and the potential development of targeted therapy in future could have broad benefits across these disorders.
Scienmag
MARCH 3, 2021
Using the model organism Caenorhabditis elegans, researchers at the University of Cologne have developed an ‘aging clock’ that reads the biological age of an organism directly from its gene expression, the transcriptome.
Pharmaceutical Technology
JUNE 13, 2023
The aberrant protein complex is essential for regulating leukaemia-promoting gene expression. A resistant mutation, MEN1-M3271, developed in one of 29 patients, detected at the end of Cycle 4, but the patient maintained stable disease through Cycle 7. The median age of RP2D patients in the study was 70.5 years (22–86 years).
BioTech 365
MARCH 24, 2021
Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research PITTSBURGH–(BUSINESS WIRE)–#RNA–Ocean Genomics (Pittsburgh, PA), a world leader in AI-based gene expression analysis and RNA biomarker … Continue (..)
Scienmag
MAY 23, 2021
Press release – Abstract 1394: Alterations in clock genes expression in Eutopic and Ectopic Endometrial Tissue New research suggests that night shift work is linked to menstrual irregularity and increased chance of developing endometriosis According to a study being presented at the 23rd European Congress of Endocrinology (e-ECE 2021), on Sunday (..)
BioTech 365
OCTOBER 6, 2020
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: The plant hormone auxin may promote disease by regulating virulence gene expression.Scientists have long known that the plant hormone auxin controls many aspects of plant growth, development, … Continue reading →
pharmaphorum
AUGUST 2, 2021
The agreement gives the company rights to spherical nucleic acid (SNA) drugs – nanoparticles with nucleic acids bound to their surfaces – which can be used to get oligonucleotides into cells to modify gene expression efficiently, and without the toxicity caused by some other delivery mechanisms.
Delveinsight
JULY 24, 2021
Another therapy by the same company named GTX-102 is also an antisense therapy; however, it silences gene expression by binding to the RNA molecule that regulates its expression. It is designed to target and inhibit the molecule that silences the paternal copy of the gene, called UBE3A antisense transcript (UBE3A-AS).
BioTech 365
JUNE 10, 2021
inter-university research group has succeeded in constructing the gene expression network behind the vascular development process in … Continue reading →
BioTech 365
SEPTEMBER 9, 2020
–(BUSINESS WIRE)–Paradise Genomics announced that it has advanced the development of their whole blood-based assay for gastric cancer by translating a gene expression profile associated with the disease into a high-throughput and cost-effective real-time PCR (RT-PCR) test. NORTHBROOK, Ill.–(BUSINESS
XTalks
JUNE 17, 2022
It blocks the activity of JAK1 and JAK2 to interfere with the JAK-STAT signaling pathway to dampen the production of inflammatory cytokines through the modulation of gene expression. Individuals can develop alopecia at any age, but most develop it during childhood or teenage years.
The Pharma Data
FEBRUARY 24, 2022
Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development. They then developed a new therapeutic approach with a potent small-molecule inhibitor of this enzyme.
XTalks
MARCH 13, 2024
Biomarker testing is being pursued to identify biological signs of the disease and provide an approach to develop personalized treatment plans for each patient. As this technology continues to evolve, it is expected to help identify glaucoma in its nascent stages of development.
XTalks
MARCH 7, 2024
Research at SRI International has highlighted the relationship between hormonal changes and sleep disruptions and developed systems to manage hot flashes. Addressing women’s health issues on this day also underscores the critical link between women’s health and broader socio-economic development.
pharmaphorum
JANUARY 13, 2022
AstraZeneca has expanded its efforts to develop new therapies targeting transcription factors – proteins that regulate processes in the cell that have become a hot topic for drug discovery in cancer and other diseases. It’s not the big pharma’s first foray into the transcription factor area.
XTalks
MAY 31, 2022
The disease usually develops around 15 to 25 years of age and can recur at any point of time in the affected individual’s life. Tapinarof treatment in a mouse model of psoriasis resulted in the downregulation of inflammatory cytokine expression in skin tissue, which involved IL17A , IL17F , IL19 , IL22 , IL23A and IL1B gene expression.
pharmaphorum
MARCH 10, 2021
Philip Gregory, chief scientific officer at bluebird, said the latest analysis showed that the integration site of the vector was in a gene called VAMP4. VAMP4 has no known association with development of AML or with processes such as cellular proliferation or genome stability that could be linked with cancer.
pharmaphorum
OCTOBER 19, 2022
The dark genome – a loose term that covers non-coding regions of the genome that are capable of regulating the expression of genes, previously rather inaccurately referred to as junk DNA – is increasingly being explored by biopharma companies for new drug targets.
Roots Analysis
NOVEMBER 3, 2023
NAD + is involved in a wide range of cellular processes, including energy metabolism, DNA repair, and gene expression. Despite their potential therapeutic benefits, NAMPT inhibitors have faced several challenges in clinical development. Several trials focused on evaluation of such drugs were discontinued in the past.
The Pharma Data
JULY 12, 2021
.” In the new study, Ghosh and colleagues replaced the first and last steps in preclinical drug discovery with two novel approaches developed within the UC San Diego Institute for Network Medicine (iNetMed), which unites several research disciplines to develop new solutions to advance life sciences and technology and enhance human health.
XTalks
NOVEMBER 6, 2020
Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The gene therapy-based vaccine targets mucosal tissues in the gastrointestinal tract, allowing for greater selectivity and targeted delivery compared to traditional vaccines.
The Pharma Data
JULY 11, 2021
Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year. Global Development Leader, Immunology at Lilly. ” About The Studies.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content